• Publications
  • Influence
Involvement of tumor necrosis factor‐α in development of hepatic injury in galactosamine‐sensitized mice
Intravenous injection of lipopolysaccharide and D‐galactosamine, at doses of 0.2 μg/kg and 800 mg/kg, respectively, elicited massive hepatic necrosis within 24 hr in C3H/HeN mice. The plasma
[Effects of E-3123, a new protease inhibitor, on several protease activities and on experimental acute pancreatitis].
TLDR
The results show that E-3123 may possess suppressing effects on pathogenesis and development of acute pancreatitis and in dogs with pancreatitis, increases in serum trypsin and lipase activities were significantly reduced by infusion of E- 3123.
Protective effects of (2E)-3-[5-(2,3-dimethoxy-6-methyl-1,4- benzoquinoyl)]-2-nonyl-2-propenoic acid on endotoxin-mediated hepatitis in mice.
TLDR
Oral pretreatment with E3330 attenuated the elevation of plasma tumor necrosis factor activity and protected mice from liver injury and inhibited the production of tumor Necrosis factor from cultured Propionibacterium acnes-elicited murine peritoneal macrophages on stimulation with lipopolysaccharide in vitro.
Protective effect of E3330, a novel quinone derivative, in galactosamine-induced hepatitis in rats.
TLDR
The results suggest that E3330 may exert its hepatoprotective effects through inhibition of an effect of endotoxin in galactosamine-induced hepatitis in rats.
Effects of rabeprazole, a gastric proton pump inhibitor, on biliary and hepatic lysosomal enzymes in rats.
TLDR
The results of the present study indicate that rabeprazoles, like omeprazole, does not influence hepatic lysosomal function and no significant differences were observed in biliary lysOSomal enzyme activity, protein content, bile flow, biliary constituents or in the plasma concentrations of lipids between the drug groups and the control group.
E3710, a New Proton Pump Inhibitor, with a Long-Lasting Inhibitory Effect on Gastric Acid Secretion
TLDR
Results show that E3710 is a long-acting inhibitor of gastric acid secretion and a promising novel therapy for acid-related diseases, such as gastroesophageal reflux disease.
Suppressive effects of E3330, a novel quinone derivative, on tumor necrosis factor-α generation from monocytes and macrophages
TLDR
Findings indicate that E3330 has a suppressive effect on TNF-α generation from monocytes/macrophages, regardless of origin or species, and this effect is based in part on the suppression of T NF-α mRNA expression.
A novel truncated glucagon-like peptide 2 (GLP-2) as a tool for analyzing GLP-2 receptor agonists.
TLDR
GLP-2(11-33) is a novel, useful tool for analyzing the mode of action of agonists and ago-allosteric modulators of GLp-2R, and suggest that the binding sites of the ago- allostericModulator and GLP- 2 overlap, at least in rat GLP -2R.
...
1
2
3
...